Claims for Patent: 10,314,855

Summary for Patent: 10,314,855

Title:	Methods relating to lung cancer
Abstract:	The methods and assays described herein relate to detection, diagnosis, and treatment of lung cancer, e.g., by detecting the level of expression of certain miRNAs described herein and/or by therapeutically increasing the level of those miRNAs.
Inventor(s):	Pavel; Ana Brandusa (New York, NY), Campbell; Joshua David (Sharon, MA), Lenburg; Marc Elliott (Brookline, MA), Spira; Avrum (Newton, MA)
Assignee:	TRUSTEES OF BOSTON UNIVERSITY (Boston, MA)
Application Number:	15/877,447
Patent Claims:	1. A method of treating lung cancer in a subject in need thereof, the method comprising administering a treatment for lung cancer to a subject determined to have a level of expression of at least 1 miRNAs selected from the group consisting of: miR-146a-5p, miR-324-5p, miR-223-3p, miR-223-5p; miR-450b-5p, miR-221-3p-miR-505-3p, and miR-582-5p; in a bronchial brushing or nose epithelial sample obtained from the subject which is decreased relative to a reference level, wherein the treatment is resection, lobesctomy, pneumonectomy, radiation therapy, stereotactic body radiotherapy, chemotherapy, or immunotherapy. 2. The method of claim 1, further comprising the first steps of obtaining a sample from a subject; and determining the level of expression of the at least 1 miRNA; and administering a treatment for lung cancer if the level of expression of the at least 1 miRNA is decreased relative to a reference level. 3. The method of claim 1, wherein the level of expression is detected for at least two miRNAs selected from the group consisting of: miR-146a-5p, miR-324-5p, miR-223-3p, miR-223-5p; miR-450b-5p, miR-221-3p-miR-505-3p, and miR-582-5p. 4. The method of claim 1, wherein the level of expression is detected for at least three miRNAs selected from the group consisting of: miR-146a-5p, miR-324-5p, miR-223-3p, miR-223-5p; miR-450b-5p, miR-221-3p-miR-505-3p, and miR-582-5p. 5. The method of claim 1, wherein the level of expression is detected for at least four miRNAs selected from the group consisting of: miR-146a-5p, miR-324-5p, miR-223-3p, miR-223-5p; miR-450b-5p, miR-221-3p-miR-505-3p, and miR-582-5p. 6. The method of claim 1, wherein the level of expression is detected for at least five miRNAs selected from the group consisting of: miR-146a-5p, miR-324-5p, miR-223-3p, miR-223-5p; miR-450b-5p, miR-221-3p-miR-505-3p, and miR-582-5p. 7. The method of claim 1, wherein the level of expression is detected for at least six miRNAs selected from the group consisting of: miR-146a-5p, miR-324-5p, miR-223-3p, miR-223-5p; miR-450b-5p, miR-221-3p-miR-505-3p, and miR-582-5p. 8. The method of claim 1, wherein the level of expression is detected for at least seven miRNAs selected from the group consisting of: miR-146a-5p, miR-324-5p, miR-223-3p, miR-223-5p; miR-450b-5p, miR-221-3p-miR-505-3p, and miR-582-5p. 9. The method of claim 1, wherein the level of expression is detected for miR-146a-5p, miR-324-5p, miR-223-3p, miR-223-5p; miR-450b-5p, miR-221-3p-miR-505-3p, and miR-582-5p. 10. The method of claim 1, wherein the level of expression is detected for at least miR-146a-5p, miR-324-5p, miR-223-3p, and miR-223-5p. 11. The method of claim 1, wherein the level of expression is detected for at least miR-146a-5p. 12. The method of claim 1, wherein the method further comprises detecting the expression level of one or more mRNAs. 13. The method of claim 1, wherein the expression level of no more than 100 miRNAs and/or mRNAs is detected. 14. A method of treating lung cancer in a subject in need thereof, the method comprising administering a treatment for lung cancer to a subject determined to have a level of expression of at least 1 miRNAs selected from the group consisting of: miR-146a-5p, miR-324-5p, miR-223-3p, miR-223-5p; miR-450b-5p, miR-221-3p-miR-505-3p, and miR-582-5p; in a bronchial brushing or nose epithelial sample obtained from the subject which is decreased relative to a reference level, wherein the treatment for lung cancer comprises an agonist of at least 1 miRNA selected from the group consisting of: miR-146a-5p, miR-324-5p, miR-223-3p, miR-223-5p; miR-450b-5p, miR-221-3p-miR-505-3p, and miR-582-5p. 15. The method of claim 1, wherein the treatment is administration of afatinib, bevacizumab, certinib, crizotinib, erlotinib, nivolumab, or ramucirumab. 16. The method of claim 1, wherein the treatment is resection, lobesctomy, or pneumonectomy. 17. The method of claim 1, wherein the treatment comprises a first step of performing resection, lobesctomy, or pneumonectomy and a second step of administering radiation therapy, stereotactic body radiotherapy, chemotherapy, or immunotherapy. 18. The method of claim 1, wherein the lung cancer is non-small cell lung cancer.

Details for Patent 10,314,855

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	AVASTIN	bevacizumab	Injection	125085	02/26/2004		2037-01-23
Eli Lilly And Company	CYRAMZA	ramucirumab	Injection	125477	04/21/2014		2037-01-23
Bristol-myers Squibb Company	OPDIVO	nivolumab	Injection	125554	12/22/2014		2037-01-23